好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Periventricular White Matter Fractional Anisotropy as a Biomarker of Cerebral Small Vessel Disease
Aging, Dementia, and Behavioral Neurology
P11 - Poster Session 11 (11:45 AM-12:45 PM)
7-007
To evaluate the utility of Diffusion Tensor Imaging (DTI)-based microstructural metrics in periventricular white matter (PVWM) versus total white matter as a biomarker of cerebral small vessel disease (CSVD).
PVWM, supplied exclusively by small arteries, has the lowest cerebral blood flow (CBF) in the brain and a high frequency of white matter hyperintensities (WMH) in aging. Accordingly, PVWM tissue may be particularly sensitive to CSVD. We compared DTI parameters in normal-appearing periventricular white matter (NA-PVWM) to normal-appearing white matter (NAWM) as a whole and assessed their correlations with WMH and vascular risk factors in an older cohort.

Multimodal MRI data from N=100 cognitively normal older subjects in the Penn Alzheimer’s Disease Research Center were analyzed. An established CBF-based PVWM mask was used to extract mean values for DTI metrics (fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD) and radial diffusivity (RD)). We derived WMH lesion masks from FLAIR MRI to calculate total WMH volume and to exclude WMH voxels from WM and PVWM regions.

Cohort mean age was 73(6) years with 61% females. All DTI metrics were significantly higher in NA-PVWM compared to NAWM (all P<0.001). Only FA in both NAWM (P=0.010) and NA-PVWM (P=0.007) was significantly associated with hypertension. None of the DTI metrics were associated with diabetes, hypercholesterolemia, or smoking. After adjustment for age and sex, diffusivity values in both NA-PVWM and NAWM correlated similarly with total WMH volume (all P<0.001, except P=0.003 for AD in NA-PVWM), whereas FA was significantly correlated with WMH volume only in NA-PVWM (P<0.001).

 

PVWM differs from total WM in microstructural characteristics derived from DTI. FA in NA-PVWM was associated with hypertension and with overall WMH burden, suggesting that FA in PVWM may be a potential biomarker of CSVD.

Authors/Disclosures
Banafsheh Shakibajahromi, MD (University of Pennsylvania, Department of Neurology)
PRESENTER
Dr. Shakibajahromi has nothing to disclose.
Sudipto Dolui, PhD (University of Pennsylvania) Dr. Dolui has nothing to disclose.
Christopher A. Brown, MD, PhD (Hospital of the University of Pennsylvania) The institution of Dr. Brown has received research support from National Institute of Health.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
David A. Wolk, MD, FAAN (University of Pennsylvania) Dr. Wolk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Wolk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Functional Neuromodulation. Dr. Wolk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GSK. The institution of Dr. Wolk has received research support from Biogen. Dr. Wolk has received publishing royalties from a publication relating to health care. Dr. Wolk has received personal compensation in the range of $5,000-$9,999 for serving as a CME speaker with Eli Lilly.
John A. Detre, MD (Hosp of the Univ of Penn) Dr. Detre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hura Imaging. The institution of Dr. Detre has received research support from NIH. Dr. Detre has received personal compensation in the range of $500-$4,999 for serving as a grant proposal reviewer with NIH, VA, European Science Foundation,Deutsche Forschungsgemeinschaft.